[Latest frontiers in pharmacotherapy for benign prostatic hyperplasia].

Alpha(1)-adrenoceptor antagonists, called alpha(1)-blockers, are the first-line treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH). Nonselective alpha(1)-blockers like prazosin were mainly used in the past, but prostate-specific alpha(1)-blockers such as tamsulosin or naftopidil are now the mainstream agents for the management of BPH, based on the function of alpha(1)-adrenoceptor subtypes. Recent studies on voiding dysfunction have clarified the association between BPH and overactive bladder (OAB), underlining the use of OAB treatment in the management of BPH, inducing the simultaneous administration of antimuscarinic agents. Every aspect of diversified BPH symptom can be controlled individually in a short period.